Literature DB >> 17088358

The Moraxella catarrhalis autotransporter McaP is a conserved surface protein that mediates adherence to human epithelial cells through its N-terminal passenger domain.

Serena L Lipski1, Christine Akimana, Jennifer M Timpe, R Mark Wooten, Eric R Lafontaine.   

Abstract

The protein McaP was previously shown to be an adhesin expressed by the Moraxella catarrhalis strain O35E, which also displays esterase and phospholipase B activities (J. M. Timpe et al., Infect. Immun. 71:4341-4350, 2003). In the present study, sequence analysis suggests that McaP is a conventional autotransporter protein that contains a 12-stranded beta-barrel transporter module (amino acids [aa] 383 to 650) linked to a surface-exposed passenger domain exhibiting lipolytic activity (aa 62 to 330). An in-frame deletion removing most of this predicted N-terminal passenger domain was engineered, and Escherichia coli expressing the truncated McaP protein exhibited greatly reduced adherence to A549 human lung epithelial cells compared to E. coli expressing wild-type McaP. Site-directed mutagenesis of a serine residue at position 62 of McaP, predicted to be important for the lipolytic activity of the protein, resulted in loss of hydrolysis of p-nitrophenyl ester of caproate. E. coli expressing this mutated McaP, however, adhered to A549 monolayers at levels greater than recombinant bacteria expressing the wild-type adhesin. These results indicate that the predicted passenger domain of McaP is involved in both the binding and the lipolytic activity of the molecule and demonstrate that the adhesive properties of McaP do not require its lipolytic activity. Sequence analysis of mcaP from eight Moraxella catarrhalis strains revealed that the gene product is highly conserved at the amino acid level (98 to 100% identity), and Western blot analysis demonstrated that a panel of 16 isolates all express McaP. Flow cytometry experiments using antibodies raised against various portions of McaP indicated that its predicted passenger domain as well as transporter module contain surface-exposed epitopes. In addition to binding to the surface of intact bacteria, these antibodies were found to decrease adherence of M. catarrhalis to A549 human lung cells by up to 47% and to reduce binding of recombinant E. coli expressing McaP by 98%. These results suggest that McaP should be considered as a potential vaccine antigen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088358      PMCID: PMC1828417          DOI: 10.1128/IAI.01330-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  64 in total

1.  The outer membrane proteins UspA1 and UspA2 of Moraxella catarrhalis are highly conserved in nasopharyngeal isolates from young children.

Authors:  Patricia Stutzmann Meier; Rolf Troller; Ioanna N Grivea; George A Syrogiannopoulos; Christoph Aebi
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

2.  Antibodies to BrkA augment killing of Bordetella pertussis.

Authors:  D C Oliver; R C Fernandez
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

3.  Characterization of the essential transport function of the AIDA-I autotransporter and evidence supporting structural predictions.

Authors:  J Maurer; J Jose; T F Meyer
Journal:  J Bacteriol       Date:  1999-11       Impact factor: 3.490

4.  The Haemophilus influenzae Hia autotransporter harbours two adhesive pockets that reside in the passenger domain and recognize the same host cell receptor.

Authors:  Sven Laarmann; David Cutter; Twyla Juehne; Stephen J Barenkamp; Joseph W St Geme
Journal:  Mol Microbiol       Date:  2002-11       Impact factor: 3.501

5.  Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species.

Authors:  G M Carlone; M L Thomas; H S Rumschlag; F O Sottnek
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

6.  Antibody response to outer membrane proteins of Moraxella catarrhalis in children with otitis media.

Authors:  K Mathers; M Leinonen; D Goldblatt
Journal:  Pediatr Infect Dis J       Date:  1999-11       Impact factor: 2.129

7.  The Hemophilus influenzae Hap autotransporter is a chymotrypsin clan serine protease and undergoes autoproteolysis via an intermolecular mechanism.

Authors:  D L Fink; L D Cope; E J Hansen; J W Geme
Journal:  J Biol Chem       Date:  2001-08-14       Impact factor: 5.157

8.  Conservation of outer membrane protein E among strains of Moraxella catarrhalis.

Authors:  T F Murphy; A L Brauer; N Yuskiw; E R McNamara; C Kirkham
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

9.  Antigenic structure of outer membrane protein E of Moraxella catarrhalis and construction and characterization of mutants.

Authors:  T F Murphy; A L Brauer; N Yuskiw; T J Hiltke
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

10.  Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice.

Authors:  David Cutter; Kathryn W Mason; Alan P Howell; Doran L Fink; Bruce A Green; Joseph W St Geme
Journal:  J Infect Dis       Date:  2002-09-16       Impact factor: 5.226

View more
  29 in total

1.  Genome analysis of Moraxella catarrhalis strain BBH18, [corrected] a human respiratory tract pathogen.

Authors:  Stefan P W de Vries; Sacha A F T van Hijum; Wolfgang Schueler; Kristian Riesbeck; John P Hays; Peter W M Hermans; Hester J Bootsma
Journal:  J Bacteriol       Date:  2010-05-07       Impact factor: 3.490

Review 2.  Potential impact of a Moraxella catarrhalis vaccine in COPD.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

3.  Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

Review 4.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

5.  Identification of a repressor of a truncated denitrification pathway in Moraxella catarrhalis.

Authors:  Wei Wang; Anthony R Richardson; Willm Martens-Habbena; David A Stahl; Ferric C Fang; Eric J Hansen
Journal:  J Bacteriol       Date:  2008-09-26       Impact factor: 3.490

6.  Moraxella catarrhalis binding to host cellular receptors is mediated by sequence-specific determinants not conserved among all UspA1 protein variants.

Authors:  Michael J Brooks; Jennifer L Sedillo; Nikki Wagner; Wei Wang; Ahmed S Attia; Henry Wong; Cassie A Laurence; Eric J Hansen; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

7.  Modular arrangement of allelic variants explains the divergence in Moraxella catarrhalis UspA protein function.

Authors:  Michael J Brooks; Jennifer L Sedillo; Nikki Wagner; Cassie A Laurence; Wei Wang; Ahmed S Attia; Eric J Hansen; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

Review 8.  A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

9.  Identification of potential therapeutic targets for Burkholderia cenocepacia by comparative transcriptomics.

Authors:  Deborah R Yoder-Himes; Konstantinos T Konstantinidis; James M Tiedje
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

10.  Identification of a bacteriocin and its cognate immunity factor expressed by Moraxella catarrhalis.

Authors:  Ahmed S Attia; Jennifer L Sedillo; Todd C Hoopman; Wei Liu; Lixia Liu; Chad A Brautigam; Eric J Hansen
Journal:  BMC Microbiol       Date:  2009-09-25       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.